Plasma procalcitonin is associated with all-cause and cancer mortality in apparently healthy men: a prospective population-based study

BMC Medicine

Research Article

Ovidiu S Cotoi¹  Jonas Manjer²  Olle Melander²  Bo Hedblad²  Gunnar Engström²  Alexandru Schiopu³ 

[1] Department of Cellular and Molecular Biology, University of Medicine and Pharmacy of Tîrgu Mureş, Tîrgu Mureş, Romania;Department of Clinical Sciences, Lund University, Lund, Sweden;Department of Clinical Sciences, Lund University, Lund, Sweden;Cardiology Clinic, Skane University Hospital, Malmö, Sweden;

关键词: Procalcitonin;    Inflammation;    Cancer;    Cardiovascular disease;    CRP;    Mortality;   

DOI  :  10.1186/1741-7015-11-180

 received in 2013-02-06, accepted in 2013-06-13,  发布年份 2013

来源: Springer

【 摘 要 】

BackgroundThe inflammatory mediator procalcitonin (PCT) has previously been associated with prognosis in myocardial infarction, cancer and sepsis patients. The importance of PCT in the general population is currently unknown. Our aim was to assess the relationship between plasma PCT and the risk of all-cause and cause-specific mortality in apparently healthy individuals with no previous history of cardiovascular disease or cancer.MethodsWe performed a prospective, population-based study on 3,322 individuals recruited from the Malmö Diet and Cancer cohort, with a median follow-up time of 16.2 years. Plasma PCT, high-sensitivity C-reactive protein (hsCRP), low-density lipoprotein (LDL), high-density lipoprotein (HDL), triglycerides and cystatin C were measured at baseline and a thorough risk factor assessment was performed for all subjects. The primary end-points of the study were all-cause mortality, cancer mortality and cardiovascular mortality.ResultsMen had higher PCT levels compared to women. In Cox proportional hazard models adjusted for age, sex, hypertension, diabetes, plasma lipids, renal function, body mass index and smoking, baseline PCT was associated with all-cause mortality and cancer mortality in men. The hazard ratio (HR) for men with PCT levels within the highest compared with the lowest quartile was 1.52 (95% confidence interval (CI) 1.07 to 2.16; P = 0.024) for all-cause mortality and 2.37 (95% CI 1.36 to 4.14; P = 0.006) for cancer mortality. Additionally, men with increased plasma PCT were found to be at a higher risk to develop colon cancer (HR per 1 SD increase = 1.49 (95% CI 1.13 to 1.95); P = 0.005). In multivariate Cox regression analyses with mutual adjustments for PCT and hsCRP, PCT was independently associated with cancer death (HR per 1 SD increase = 1.28 (95% CI 1.10 to 1.49); P = 0.001) and hsCRP with cardiovascular death (HR per 1 SD increase = 1.42 (95% CI 1.11 to 1.83); P = 0.006) in men. We found no significant correlations between baseline PCT or hsCRP and incident cancer or cardiovascular death in women.ConclusionsWe disclose for the first time important independent associations between PCT and the risk for all-cause and cancer mortality in apparently healthy men. Our findings warrant further investigation into the mechanisms underlying the relationship between PCT and cancer.

【 授权许可】

Unknown   
© Cotoi et al.; licensee BioMed Central Ltd. 2013. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.